Current Cardiovascular Risk Reports

, Volume 1, Issue 4, pp 296–302

COX-2, NSAIDs, and cardiovascular risk


DOI: 10.1007/s12170-007-0048-y

Cite this article as:
McGettigan, P. & Henry, D. Curr Cardio Risk Rep (2007) 1: 296. doi:10.1007/s12170-007-0048-y


Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Hull York Medical SchoolUniversity of HullHullEngland

Personalised recommendations